ArticleBlood2011
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.
Article in Blood, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 111 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
111 citing papers in PubMed, 197 citations in OpenAlex.
- Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1-Associated Adult T-cell Leukemia/lymphoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Trial
- Monocyte-Macrophage Lineages in Cancer: Biology, Plasticity, and Therapeutic Targeting.Cancer biome and targeted therapy · 2026Article
- In vivo safety evaluation method for nanomaterials for cancer therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Review
- Immunotherapy-induced cytotoxic T follicular helper cells reduce numbers of retrovirus-infected reservoir cells in B cell follicles.PLoS pathogens · 2023Article
- 4-1BB: A promising target for cancer immunotherapy.Frontiers in oncology · 2022Review
- Article
- Inflammation and tumor progression: signaling pathways and targeted intervention.Signal transduction and targeted therapy · 2021Article
- Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies.Journal of clinical medicine · 2020Review
- Review
- Review
- CD137, an attractive candidate for the immunotherapy of lung cancer.Cancer science · 2020Review
- Biology drives the discovery of bispecific antibodies as innovative therapeutics.Antibody therapeutics · 2020Review
- Characterization and Comparison of GITR Expression in Solid Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma.Cancer immunology research · 2019Article
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors.Journal for immunotherapy of cancer · 2019Article
- An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer.International journal of molecular sciences · 2019Review
- NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives.Annals of translational medicine · 2019Review
- A Novel Form of 4-1BBL Prevents Cancer Development via Nonspecific Activation of CD4Cancer research · 2019Article
- Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy.International journal of molecular sciences · 2019Review
- The Common Costimulatory and Coinhibitory Signaling Molecules in Head and Neck Squamous Cell Carcinoma.Frontiers in immunology · 2019Review
51 more citing papers are in PubMed but not listed here.
Corrections and comments
- Retraction · 2019-07-11Concerns/Issues about Image · Investigation by Company/Institution ·
- Retracted
Authors and funding
14 authors at 5 institutions in 2 countries.
Funding
Abstract
Antibody-dependent cell-mediated cytotoxicity (ADCC), which is largely mediated by natural killer (NK) cells, is thought to play an important role in the efficacy of rituximab, an anti-CD20 monoclonal antibody (mAb) used to treat patients with B-cell lymphomas. CD137 is a costimulatory molecule expressed on a variety of immune cells after activation, including NK cells. In the present study, we show that an anti-CD137 agonistic mAb enhances the antilymphoma activity of rituximab by enhancing ADCC. Human NK cells up-regulate CD137 after encountering rituximab-coated tumor B cells, and subsequent stimulation of these NK cells with anti-CD137 mAb enhances rituximab-dependent cytotoxicity against the lymphoma cells. In a syngeneic murine lymphoma model and in a xenotransplanted human lymphoma model, sequential administration of anti-CD20 mAb followed by anti-CD137 mAb had potent antilymphoma activity in vivo. These results support a novel, sequential antibody approach against B-cell malignancies by targeting first the tumor and then the host immune system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.